Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
Date:2/28/2011

CAMBRIDGE, Mass., Feb. 28, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2010. At December 31, 2010, Idenix's cash and cash equivalents totaled $46.1 million.

Business HighlightsIDX184 Update In February 2011, the U.S. Food and Drug Administration (FDA) removed the full clinical hold for IDX184. The program was placed on partial clinical hold, which allows Idenix to resume clinical trials involving IDX184 immediately. Idenix plans to initiate a Phase IIb 12-week clinical trial of IDX184 in combination with pegylated interferon and ribavirin in the second half of 2011. Under the partial clinical hold, Idenix will share interim data from the Phase IIb study with the FDA.

IDX375, an HCV Non-Nucleoside Polymerase Inhibitor In the first quarter of 2011, Idenix completed a three-day proof-of-concept study of IDX375 in treatment-naïve genotype 1-infected patients. Mean viral load reductions after three days of IDX375 monotherapy were 1.3, 2.3, and 2.7 log(10) IU/mL at doses of 100, 200, and 400 mg BID, respectively. Overall, IDX375 was generally safe and well-tolerated at the three doses tested.

HCV NS5A Inhibitor ProgramIdenix is developing NS5A compounds with pan-genotypic activity. Two drug candidates have been selected for preclinical development, and Idenix plans to file an Investigational New Drug (IND) application or Clinical Trial Application (CTA) for one of these candidates in 2011.

HCV Protease Inhibitor Follow-On ProgramIdenix has discontinued further development of IDX320 following its conclusion that IDX320 likely caused the observed toxicity in the drug-drug interaction (DDI) study with IDX184. I
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
8. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
9. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
10. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Bed bugs compromised Penn State. A report ... Meanwhile, My Cleaning Products offered complimentary samples of its bed ... without using harmful chemical elements. , Based on the ... building was actually a dormitory , My Cleaning Products ... May 13 and bed bug presence was confirmed on May ...
(Date:5/23/2013)... DE (PRWEB) May 23, 2013 Just released ... by executive coach and author Barbara Roche: “Commit to Confidence: ... Out.” , Filled with helpful tips and quotes from the ... business leaders, and tangible exercises that readers can do on ... how to achieve their personal and professional goals. ...
(Date:5/22/2013)... 22, 2013 iLuv Creative Technology, the ... for the mobile lifestyle, announces they are now shipping ... manage multiple iPad devices efficiently. Winner of the 2013 ... Good Design award, MultiCharger-X is revolutionizing the way businesses, ... is deployed. , MultiCharger-X (iAD910) combines ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
Breaking Biology Technology:Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... DIEGO, Nov. 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... of ADVENTRX, is scheduled to present at the Rodman ... scheduled to present,on Tuesday, November 11th, 2008 at 2:50 ... place November 10-12, 2008 at the,Palace Hotel in New ...
... technology is one of the rapidly growing markets in life science ... is projected to reach $2.2 billion. Major factors that continue to ... the existing and emerging technologies. , ... San Jose, ...
Cached Biology Technology:Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... tripled in the last 25 years, putting many children at ... in Academic Pediatrics by an obesity expert at ... Center. "Children are not only becoming obese, but ... Skelton, M.D., lead author and director of the Brenner FIT ...
... Many experimental studies have found that physical exercise ... risks of cardiovascular disease; however, few of these ... ethnic breakdowns. Now, a long-term study of over ... gender- specific data on the cholesterol effects of ...
... from CSIRO,s Food Futures Flagship have made a breakthrough ... noses, (e-noses) by developing a system for comparing their ... fly. "Although e-noses already have many uses such ... air quality they are not as discriminating as ...
Cached Biology News:Research shows rates of severe childhood obesity have tripled 2Health benefits of physical activity more pronounced in women 2E-Noses: Testing their mettle against fly noses 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
...
Biology Products: